Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Bailly, B ^a,b,c   Richard, C A ^d   Sharma, G ^e   Wang, L ^a   Johansen, L ^f   Cao, J ^c,g   Pendharkar, V ^e   Sharma, D C ^e   Galloux, M ^d   Wang, Y ^a   Cui, R ^a   Zou, G ^a   Guillon, P ^e   Von Itzstein, M ^e   Eleouet J F ^d   Altmeyer, R ^a,b,c,e,f,g  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b GRIFFITH UNIVERSITY   (Australia)

^c SHANDONG UNIVERSITY   (China)

^d INRA Institut National de la Recherche Agronomique   (France)

^e CombinatoRx Singapore ^*  (Singapore)

^f Horizon CombinatoRx   (United States)

^g Qingdao Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; CYCLOPAMINE; DNA DIRECTED RNA POLYMERASE; JERVINE; SMOOTHENED PROTEIN; VERATRUM ALKALOID; VIRAL PROTEIN;

ANIMAL; ANTIVIRAL RESISTANCE; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; METABOLISM; MOLECULAR MODEL; PHYSIOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VERATRUM; VIROLOGY; VIRUS REPLICATION;

ALKALOIDS; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, VIRAL; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MICE, INBRED BALB C; MODELS, MOLECULAR; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SMOOTHENED RECEPTOR; TRANSCRIPTION, GENETIC; VERATRUM; VERATRUM ALKALOIDS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84969981386     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25806     Document Type: Article

References (58)

1. Karron, R. & Collins, P. In Fields Virology (eds. Knipe, D. & Howley, P.) 1497-1526 (Lippincott Williams & Wilkins, 2007).
2. Nair, H. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet 375, 1545-1555 (2010).
3. Hall, C. B. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344, 1917-1928 (2001).
4. Johnstone, J., Majumdar, S. R., Fox, J. D. & Marrie, T. J. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 134, 1141-1148 (2008).
5. Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749-1759 (2005).
6. Falsey, A. R. & Walsh, E. E. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 13, 371-384 (2000).
7. Resch, B., Kurath, S. & Manzoni, P. Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants. Open Microbiol. J. 5, 135-143 (2011).
8. Chu, H. Y. & Englund, J. A. Respiratory syncytial virus disease: prevention and treatment. Curr. Top. Microbiol. Immunol. 372, 235-258 (2013).
9. Hussman, J. M., Li, A., Paes, B. & Lanctôt, K. L. A review of cost-effectiveness of palivizumab for respiratory syncytial virus. Expert Rev. Pharmacoecon. Outcomes Res. 12, 553-567 (2012).
10. Smith, D. W. et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N. Engl. J. Med. 325, 24-29 (1991).
11. Wyde, P. R. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 39, 63-79 (1998).
12. Wyde, P. R. et al. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 68, 18-26 (2005).
13. DeVincenzo, J. P. et al. Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study. N. Engl. J. Med. 371, 711-722 (2014).
14. Mackman, R. L. et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J. Med. Chem. 58, 1630-1643 (2015).
15. Cianci, C. et al. Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection. Antimicrob. Agents Chemother. 48, 2448-2454 (2004).
16. Olszewska, W. et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur. Respir. J. 38, 401-408 (2011).
17. Chapman, J. et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 51, 3346-3353 (2007).
18. Challa, S. et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob. Agents Chemother. 59, 1080-1087 (2015).
19. Wang, G. et al. Discovery of 4′-chloromethyl-2′-deoxy-3′, 5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J. Med. Chem. 58, 1862-1878 (2015).
20. Collins, P. L., Hill, M. G., Cristina, J. & Grosfeld, H. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc. Natl. Acad. Sci. USA 93, 81-85 (1996).
21. Blondot, M.-L. et al. Structure and Functional Analysis of the RNA- and Viral Phosphoprotein-Binding Domain of Respiratory Syncytial Virus M2-1 Protein. PLoS Pathog. 8, e1002734 (2012).
22. Tran, T.-L. et al. The Respiratory Syncytial Virus M2-1 Protein Forms Tetramers and Interacts with RNA and P in a Competitive Manner. J. Virol. 83, 6363-6374 (2009).
23. Tawar, R. G. et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 326, 1279-1283 (2009).
24. Fearns, R. & Collins, P. L. Role of the M2-1 Transcription Antitermination Protein of Respiratory Syncytial Virus in Sequential Transcription. J. Virol. 73, 5852-5864 (1999).
25. Hardy, R. W. & Wertz, G. W. The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J. Virol. 72, 520-526 (1998).
26. Tanner, S. J. et al. Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation. Proc. Natl. Acad. Sci. USA 111, 1580-1585 (2014).
27. Taipale, J. et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406, 1005-1009 (2000).
28. Chen, J. K., Taipale, J., Cooper, M. K. & Beachy, P. A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16, 2743-2748 (2002).
29. Ingham, P. W. & McMahon, A. P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15, 3059-3087 (2001).
30. Dessinioti, C., Plaka, M. & Stratigos, A. J. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Future Oncol. Lond. Engl. 10, 927-936 (2014).
31. Bender, M. H. et al. Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling. Cancer Res. 71, 2819-2819 (2011).
32. Wang, C. et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature 497, 338-343 (2013).
33. Rominger, C. M. et al. Evidence for Allosteric Interactions of Antagonist Binding to the Smoothened Receptor. J. Pharmacol. Exp. Ther. 329, 995-1005 (2009).
34. Sinha, S. & Chen, J. K. Purmorphamine activates the Hedgehog pathway by targeting Smoothened. Nat. Chem. Biol. 2, 29-30 (2006).
35. Lin, T. L. & Matsui, W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther. 5, 47-58 (2012).
36. Heretsch, P., Tzagkaroulaki, L. & Giannis, A. Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives. Angew. Chem. Int. Ed Engl. 49, 3418-3427 (2010).
37. Cianci, C. et al. Orally Active Fusion Inhibitor of Respiratory Syncytial Virus. Antimicrob. Agents Chemother. 48, 413-422 (2004).
38. Cooper, M. K., Porter, J. A., Young, K. E. & Beachy, P. A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280, 1603-1607 (1998).
39. Jimeno, A. et al. Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. Clin. Cancer Res. 19, 2766-2774 (2013).
40. Tremblay, M. R. et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J. Med. Chem. 52, 4400-4418 (2009).
41. Robarge, K. D. et al. GDC-0449-A potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19, 5576-5581 (2009).
42. Stanton, B. Z. et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat. Chem. Biol. 5, 154-156 (2009).
43. Choi, S. S. et al. Upregulation of Hedgehog Pathway is Associated with Cellular Permissiveness for Hepatitis C Virus Replication. Hepatology 54, 1580-1590 (2011).
44. Lahaye, X. et al. Functional Characterization of Negri Bodies (NBs) in Rabies Virus-Infected Cells: Evidence that NBs Are Sites of Viral Transcription and Replication. J. Virol. 83, 7948-7958 (2009).
45. Heinrich, B. S., Cureton, D. K., Rahmeh, A. A. & Whelan, S. P. J. Protein Expression Redirects Vesicular Stomatitis Virus RNA Synthesis to Cytoplasmic Inclusions. PLoS Pathog 6, e1000958 (2010).
46. Tiong-Yip, C.-L. et al. Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob. Agents Chemother. 58, 3867-3873 (2014).
47. Laganas, V. A. et al. Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen. Antiviral Res. 115, 71-74 (2015).
48. Xiong, H. et al. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor. Bioorg. Med. Chem. Lett. 23, 6789-6793 (2013).
49. Mousseau, G. et al. An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription. Cell Host Microbe 12, 97-108 (2012).
50. Plant, H. et al. High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors. J. Biomol. Screen. 20, 597-605 (2015).
51. Boukhvalova, M. S., Prince, G. A. & Blanco, J. C. Inactivation of respiratory syncytial virus by zinc finger reactive compounds. Virol. J. 7, 20 (2010).
52. Cancellieri, M. et al. In silico structure-based design and synthesis of novel anti-RSV compounds. Antiviral Res. 122, 46-50 (2015).
53. Owens, C. M. et al. Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication. Mol. Syst. Biol. 6, 375 (2010).
54. Bailly, B. et al. A dual drug regimen synergistically blocks human parainfluenza virus infection. Sci. Rep. 6, 24138 (2016).
55. Buchholz, U. J., Finke, S. & Conzelmann, K. K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73, 251-259 (1999).
56. Galloux, M. et al. Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNAfree nucleoprotein. J. Virol. 89, 3484-3496 (2015).
57. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676-682 (2012).
58. Castagné, N. et al. Biochemical characterization of the respiratory syncytial virus P-P and P-N protein complexes and localization of the P protein oligomerization domain. J. Gen. Virol. 85, 1643-1653 (2004).